trenzyme GmbH is a privately owned German Contract Research Organization (CRO) offering a wide range of highly customized services in cell line development and recombinant protein production. Since 2000, trenzyme has been a valued research partner of national and international clients, ranging from academia and small biotechs to big pharmaceutical companies.



PEGS Europe, 9-12 November, 2020, Virtual event

Talk: High-Yield Production of SARS-CoV-2 Proteins: From Small Scale Transfection to GMP Compliant Process.
To support research groups for development of serological tests, generation of high-affinity antibodies and new vaccine candidates, trenzyme has developed a platform for rapid production of high-quality recombinant SARS-CoV-2 proteins by transient transfection, high-producer cell lines and even GMP compliant production cell lines for development of the intranasal vaccine XPOVAX.

Presented by Reinhold Horlacher, PhD, Managing Director at trenzyme.


Expert podcast: Supporting COVID-19 vaccine strategies

Listen to the post-PEGS EU interview of trenzyme’s Director Reinhold Horlacher. We sat down virtually with Reinhold to get to know more about trenzyme’s strategy to support the scientific community in the development of serological tests and in the generation of high-affinity antibodies for novel vaccine candidates.

Presented by Reinhold Horlacher, PhD, Managing Director at trenzyme & Alengo Nyamay’antu, PhD, Scientific Communication Specialist at Polyplus-transfection.